Rebekka🧊Pro

Eli Lilly Completes Acquisition of Psychedelic Drug Developer AtaiBeckley This morning, AtaiBeckley shareholders approved the company’s acquisition by Eli Lilly in a deal valued at up to $3.8 billion. It marks the largest foray into the psychedelics field by an established pharmaceutical company to date. The transaction was first announced in July after months of back and forth between the pair, who settled on terms that feature an upfront payment of $6.75 per share ($2.8 billion) plus up to $2.50 per share across three milestones that cover both the company’s lead intranasal 5-MeO-DMT candidate (BPL-003) as well as its DMT candidate, VLS-01. At today’s special meeting, shareholders endorsed the deal.